Medicenna Therapeutics Corp. (MDNA.TO)
| Previous Close | 1.9500 |
| Open | 2.0900 |
| Bid | 2.4800 x N/A |
| Ask | 2.4900 x N/A |
| Day's Range | 2.0900 - 2.6200 |
| 52 Week Range | 0.2150 - 2.6200 |
| Volume | |
| Avg. Volume | 166,893 |
| Market Cap | 173.397M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Jun 25, 2024 - Jul 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.56 |
- GlobeNewswire
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement
GlobeNewswireMedicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced to
- Baystreet
Stocks in play: Medicenna Therapeutics Corp.
Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions ...
